[Market Focus] BuKwang Pharm Surges 13% Early on Mid- to Long-Term Vision and High-Dividend Expectations

BuKwang Pharm is experiencing an early surge of over 13% in its stock price on March 25, 2026, driven by the announcement of its mid- to long-term vision and high-dividend policy at the shareholders' meeting.

As of 9:50 a.m. on March 25, BuKwang Pharm was trading at 8,050 won on the Korea Exchange, up 13.22% from the previous session.

Previously, at the shareholders' meeting held the day before, BuKwang Pharm announced its mid- to long-term vision to join the top 20 domestic pharmaceutical companies in terms of sales by 2030.

The company also unveiled a high-dividend policy aimed at enhancing shareholder value. BuKwang Pharm decided to pay a total dividend of 12.3 billion won, combining the interim dividend of 50 won per share that was paid in November last year and the year-end dividend of 75 won per share approved at the shareholders' meeting.

According to BuKwang Pharm, this dividend enables the company to meet the criteria for high-dividend companies, allowing shareholders to benefit from separate taxation on dividend income.

This content was produced with the assistance of AI translation services.